title: Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
abstract: Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab - a PD-1 inhibitor - is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.
authors.affiliation: a Department of Medicine/Division of Hematology , Mayo Clinic , Rochester , MN , USA.
authors.forename: Jose C
authors.initials: JC
authors.lastname: Villasboas
authors.affiliation: a Department of Medicine/Division of Hematology , Mayo Clinic , Rochester , MN , USA.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Ansell
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000079963:Brentuximab Vedotin; D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; D000079963:Brentuximab Vedotin
keywords: Hodgkin lymphoma; PD-1; PD-L1; checkpoint inhibitors; immune-related adverse events; immunotherapy; nivolumab